全文获取类型
收费全文 | 2773篇 |
免费 | 200篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 54篇 |
妇产科学 | 86篇 |
基础医学 | 401篇 |
口腔科学 | 22篇 |
临床医学 | 263篇 |
内科学 | 655篇 |
皮肤病学 | 124篇 |
神经病学 | 453篇 |
特种医学 | 52篇 |
外科学 | 254篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 161篇 |
眼科学 | 33篇 |
药学 | 200篇 |
中国医学 | 7篇 |
肿瘤学 | 206篇 |
出版年
2023年 | 37篇 |
2022年 | 39篇 |
2021年 | 130篇 |
2020年 | 87篇 |
2019年 | 96篇 |
2018年 | 110篇 |
2017年 | 93篇 |
2016年 | 108篇 |
2015年 | 134篇 |
2014年 | 154篇 |
2013年 | 195篇 |
2012年 | 264篇 |
2011年 | 245篇 |
2010年 | 115篇 |
2009年 | 119篇 |
2008年 | 183篇 |
2007年 | 176篇 |
2006年 | 151篇 |
2005年 | 142篇 |
2004年 | 113篇 |
2003年 | 100篇 |
2002年 | 91篇 |
2001年 | 17篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 11篇 |
1997年 | 14篇 |
1996年 | 4篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 3篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1962年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有2997条查询结果,搜索用时 239 毫秒
1.
Davide Fiore Bavaro Flavia Balena Luigi Ronga Fabio Signorile Federica Romanelli Stefania Stolfa Eleonora Sparapano Carmela De Carlo Adriana Mosca Laura Monno Gioacchino Angarano Annalisa Saracino 《Journal de Mycologie Médicale》2022,32(1):101206
An increased number of patients is at risk of Candida spp. bloodstream infection (CBSI) in modern medicine. Moreover, the rising of antifungal resistance (AR) was recently reported. All consecutive CBSI occurred in our Hospital (consisting of 1,370 beds) between 2015 and 2018, were reviewed. For each case, Candida species, AR pattern, ward involved and demographic data of patients were recorded. Overall, 304 episodes of CBSI occurred, with a median (q1:first-,q3:third quartile) of 77 (71-82) CBSI/year. Over the years, a significant increase of CBSI due to C. albicans compared to non-albicans strains was recorded in medical wards (from 65% to 71%, p=0.030), while this ratio remained stable in others. An increase of resistant strains to multiple antifungals such as C. guillermondii was noticed in recent years (from 0% to 9.8%, p=0.008). Additionally, from 2015 to 2018 an increase in fluconazole-resistance was recorded in our Hospital (from 7.4% to 17.4%, p=0.025) and a slight increase in voriconazole-resistance (from 0% to 7% in 2018, p=0.161) was observed, while resistance to echinocandin and amphotericin B remained firmly below 2%.This study suggests a rapid spread of antifungal resistance in our Hospital; therefore, an appropriate antifungal stewardship programs is urgently warranted. 相似文献
2.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
3.
4.
5.
Federica Miglietta Maria Vittoria Dieci Vassilena Tsvetkova Gaia Griguolo Grazia Vernaci Alice Menichetti Giovanni Faggioni Tommaso Giarratano Eleonora Mioranza Elisa Genovesi Enrico Cumerlato Michele Bottosso Tania Saibene Silvia Michieletto Marcello Lo Mele Pierfranco Conte Valentina Guarneri 《The oncologist》2020,25(9):e1355-e1362
6.
7.
8.
Francesco Pierantoni Umberto Basso Marco Maruzzo Evelina Lamberti Davide Bimbatti Giuseppina Tierno Eleonora Bergo Antonella Brunello Vittorina Zagonel 《Journal of Geriatric Oncology》2021,12(2):290-297
BackgroundThere is poor data on the prognostic role of Comprehensive Geriatric Assessment (CGA) in older patients with metastatic renal cell carcinoma (mRCC) treated with first line Tyrosine Kinase Inhibitors (TKIs).Materials and MethodsWe retrospectively reviewed the clinical charts of mRCC patients older than 70 years treated at our Institute with first-line Sunitinib or Pazopanib for at least 6 months. Every patient received a CGA at baseline and was identified as fit, vulnerable or frail according to Balducci's Criteria. We then assessed the impact of CGA category on survival, disease control and tolerability of TKIs.ResultsWe identified 86 eligible patients. Median age: 74.5 years, 56% males; 45.4% were fit, 37.2% vulnerable and 17.4% frail at CGA. There were no significant differences in the rate of Grade (G)1–2 and G3-4 toxicities, dose reduction rates, PFS and OS between Sunitinib and Pazopanib. Fit, vulnerable and frail patients achieved significantly different median PFS (18.9 vs 11.2 vs 5.1 months; p < 0.001) and OS (35.5 vs 14.6 vs 10.9 months; p < 0.001). Patients categorized as fit had higher chance of receiving a second-line treatment (66.6% vs 28.9% in vulnerable/frail; p = 0.002). The incidence of G3/4 events was significantly lower in the fit subgroup (19% vs 45% in vulnerable/frail; p = 0.0025).ConclusionsIn our retrospective single-center experience, CGA could accurately discriminate patients with higher risk of experiencing G3/4 toxicities, shorter PFS, and lower chance of receiving a second line treatment. CGA strongly impacted on OS, independently from International mRCC Database Consortium (IMDC) classification. 相似文献
9.
Gastaldi Matteo Scaranzin Silvia Jarius Sven Wildeman Brigitte Zardini Elisabetta Mallucci Giulia Rigoni Eleonora Vegezzi Elisa Foiadelli Thomas Savasta Salvatore Banfi Paola Versino Maurizio Benedetti Luana Novi Giovanni Mancardi Margherita Maria Giacomini Thea Annovazzi Pietro Baroncini Damiano Ferraro Diana Lampasona Vito Reindl Markus Waters Patrick Franciotta Diego 《Journal of neurology》2020,267(12):3555-3564
Journal of Neurology - The detection of antibodies to myelin oligodendrocyte glycoprotein (MOG) is fundamental for the identification of MOG antibody-associated disorders (MOGAD), and the... 相似文献
10.
Ju-Fang Shi PhD Le Wang PhD Jian-Chao Ran MPH Hong Wang MB Cheng-Cheng Liu MB Hai-Zeng Zhang MD Lin Yang MD Su-Sheng Shi MD Li-Ming Jiang MD Jin-Hu Fan BS Yue-Ming Zhang MD Wei-Hu Wang MD Jian-Song Ren PhD Lin Zhu MPH Zhao-Xu Zheng MD Yong-Kun Sun MD Shuang-Mei Zou MD Jun Jiang MD Bo Chen MD Hong-Da Chen PhD Guo-Xiang Liu PhD Li Yang PhD Yun-Chao Huang MD Lan-Wei Guo PhD De-Bin Wang PhD Yong-Zhen Zhang MPH A-Yan Mao MPH Jia-Lin Wang MD Ji-Yong Gong MD Dong-Hua Wei MD Wu-Qi Qiu PhD Bing-Bing Song MPH Kai Zhang MD Ni Li PhD Eleonora Feletto PhD Jie-Bin Lew PhD You-Lin Qiao PhD Wan-Qing Chen PhD Min Dai PhD Jie He MD 《Cancer》2021,127(11):1880-1893